AU2019218518B2 - CD38 protein antibody and application thereof - Google Patents

CD38 protein antibody and application thereof Download PDF

Info

Publication number
AU2019218518B2
AU2019218518B2 AU2019218518A AU2019218518A AU2019218518B2 AU 2019218518 B2 AU2019218518 B2 AU 2019218518B2 AU 2019218518 A AU2019218518 A AU 2019218518A AU 2019218518 A AU2019218518 A AU 2019218518A AU 2019218518 B2 AU2019218518 B2 AU 2019218518B2
Authority
AU
Australia
Prior art keywords
antibody
seq
antigen
binding
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019218518A
Other languages
English (en)
Other versions
AU2019218518A1 (en
Inventor
Xiaoran DING
Ming LV
Shiwei MIAO
Bin Tan
Xuegong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Sumgen Biotech Co Ltd
Sumgen MAb Beijing Biotech Co Ltd
Original Assignee
Hangzhou Sumgen Biotech Co Ltd
Sumgen MAb Beijing Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Sumgen Biotech Co Ltd, Sumgen MAb Beijing Biotech Co Ltd filed Critical Hangzhou Sumgen Biotech Co Ltd
Publication of AU2019218518A1 publication Critical patent/AU2019218518A1/en
Application granted granted Critical
Publication of AU2019218518B2 publication Critical patent/AU2019218518B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2019218518A 2018-02-12 2019-02-11 CD38 protein antibody and application thereof Active AU2019218518B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810144817.4A CN110144008B (zh) 2018-02-12 2018-02-12 Cd38蛋白抗体及其应用
CN201810144817.4 2018-02-12
PCT/CN2019/074806 WO2019154421A1 (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用

Publications (2)

Publication Number Publication Date
AU2019218518A1 AU2019218518A1 (en) 2020-10-01
AU2019218518B2 true AU2019218518B2 (en) 2025-07-10

Family

ID=67547850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019218518A Active AU2019218518B2 (en) 2018-02-12 2019-02-11 CD38 protein antibody and application thereof

Country Status (11)

Country Link
US (1) US11713357B2 (enExample)
EP (1) EP3753955A4 (enExample)
JP (1) JP7333523B2 (enExample)
KR (1) KR102770962B1 (enExample)
CN (3) CN110144008B (enExample)
AU (1) AU2019218518B2 (enExample)
BR (1) BR112020016271A2 (enExample)
CA (1) CA3091492C (enExample)
SG (1) SG11202007443XA (enExample)
TW (1) TWI818952B (enExample)
WO (1) WO2019154421A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
CN114075283A (zh) * 2020-08-12 2022-02-22 三生国健药业（上海）股份有限公司 结合人cd38的抗体、其制备方法和用途
CN114075285B (zh) * 2020-08-20 2023-05-30 瑞阳(苏州)生物科技有限公司 抗人cd38人源化单克隆抗体及其应用
WO2023098813A1 (en) * 2021-12-03 2023-06-08 Nanjing Leads Biolabs Co., Ltd. Antibodies binding cd38 and uses thereof
WO2024183634A1 (en) * 2023-03-09 2024-09-12 Norroy Bioscience Co., Ltd. Radiolabeled antibody conjugates and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042309A2 (en) * 2005-10-12 2007-04-19 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2010040209A1 (en) * 2008-10-06 2010-04-15 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
WO2012092612A1 (en) * 2010-12-30 2012-07-05 Takeda Pharmaceutical Company Limited Anti-cd38 antibodies
WO2016180958A1 (en) * 2015-05-13 2016-11-17 Morphosys Ag Treatment for multiple myeloma (mm)
WO2016187546A1 (en) * 2015-05-20 2016-11-24 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
WO2018224683A1 (en) * 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
RU2402568C2 (ru) 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL3827845T3 (pl) * 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
JP7679196B2 (ja) 2017-06-08 2025-05-19 ブラック ベルト セラピューティクス リミテッド Ｃｄ３８調節抗体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042309A2 (en) * 2005-10-12 2007-04-19 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2010040209A1 (en) * 2008-10-06 2010-04-15 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
WO2012092612A1 (en) * 2010-12-30 2012-07-05 Takeda Pharmaceutical Company Limited Anti-cd38 antibodies
WO2016180958A1 (en) * 2015-05-13 2016-11-17 Morphosys Ag Treatment for multiple myeloma (mm)
WO2016187546A1 (en) * 2015-05-20 2016-11-24 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
WO2018224683A1 (en) * 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. DECKERT ET AL, CLINICAL CANCER RESEARCH, vol. 20, no. 17, 2014, pages 4574 - 4583 *
SMITHSON ET AL.: "TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion | The Journal of Immunology", 2017, Retrieved from *

Also Published As

Publication number Publication date
TWI818952B (zh) 2023-10-21
EP3753955A1 (en) 2020-12-23
CN114835809A (zh) 2022-08-02
CN111712521B (zh) 2022-03-15
EP3753955A4 (en) 2021-12-08
WO2019154421A1 (zh) 2019-08-15
RU2020129820A3 (enExample) 2022-03-14
JP7333523B2 (ja) 2023-08-25
US11713357B2 (en) 2023-08-01
TW201934577A (zh) 2019-09-01
KR102770962B1 (ko) 2025-02-24
AU2019218518A1 (en) 2020-10-01
KR20200120937A (ko) 2020-10-22
CA3091492C (en) 2023-10-10
US20210024645A1 (en) 2021-01-28
CA3091492A1 (en) 2019-08-15
CN111712521A (zh) 2020-09-25
CN110144008B (zh) 2021-03-19
RU2020129820A (ru) 2022-03-14
CN110144008A (zh) 2019-08-20
BR112020016271A2 (pt) 2020-12-15
SG11202007443XA (en) 2020-09-29
JP2021512652A (ja) 2021-05-20

Similar Documents

Publication Publication Date Title
AU2019218518B2 (en) CD38 protein antibody and application thereof
CN110407941B (zh) Cd39的高亲和力抗体及其用途
JP7533897B2 (ja) 融合タンパク質およびその使用
JP2022527705A (ja) 融合タンパク質およびその使用
CN110343180B (zh) 抗ctla-4抗体及其应用
CN116262789A (zh) 嵌合的抗cd27抗体
CN116262788A (zh) 抗cd27抗体分子
CN116262790A (zh) 嵌合的抗cd27抗体组合物及其应用
CN116262135A (zh) 抗cd27抗体组合物及其用途
US20230272067A1 (en) Human monoclonal antibodies against tigit for immune related diseases
EP4438731A1 (en) Fusion protein comprising sirp? mutant
EP4279509A1 (en) Garp protein antibody and application thereof
US20230250186A1 (en) Cd38 protein antibody and application thereof
US20230167197A1 (en) Anti-ceramide antibodies
HK40034156A (en) Cd38 protein antibody and application thereof
CN114075283A (zh) 结合人cd38的抗体、其制备方法和用途
CN114075285A (zh) 抗人cd38人源化单克隆抗体及其应用
RU2776795C2 (ru) Антитела к белку cd38 и их применение
HK40029523A (en) Cd38 protein antibody and application thereof
HK40029523B (zh) Cd38蛋白抗体及其应用
WO2021143858A1 (en) ANTI-NKp30 ANTIBODIES AND METHODS OF USE
HK40006534B (zh) Cd38蛋白抗体及其应用
HK40006534A (en) Cd38 protein antibody and its application
HK40016809A (en) High affinity antibodies to cd39 and uses thereof
HK40016809B (en) High affinity antibodies to cd39 and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)